U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C6H5O7.3Zn
Molecular Weight 574.426
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC CITRATE

SMILES

[Zn++].[Zn++].[Zn++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=WGIWBXUNRXCYRA-UHFFFAOYSA-H
InChI=1S/2C6H8O7.3Zn/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6

HIDE SMILES / InChI
Molecular Formula C6H5O7
Molecular Weight 189.0997
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttp://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/https://www.google.com/patents/US3130034http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.t3db.ca/toxins/T3D0733http://www.hmdb.ca/metabolites/HMDB01303
Curator's Comment: description was created based on several sources, including https://www.drugs.com/dosage/zinc-sulfate.html | https://www.ncbi.nlm.nih.gov/pubmed/10721938 | https://www.drugbank.ca/drugs/DB01593 | https://www.ncbi.nlm.nih.gov/pubmed/17132019

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

CNS Activity

Originator

Smithson, R.
38
Curator's Comment: Centuries before zinc was recognized as a distinct element, zinc ores were used for making brass (a mixture of copper and zinc). A brass dating from between 1400-1000 BC has been found in Palestine. An alloy containing 87% zinc was found in prehistoric ruins in Transylvania. The smelting of zinc ores with copper was apparently discovered in Cyprus and was used later by the Romans. Metallic zinc was produced in the 13th century in India by reducing calamine (zinc carbonate, ZnCO3) with organic substances such as wool. The metal was rediscovered later in Europe. William Champion set up a zinc industry in Bristol (England) in the 1740s.

Approval Year

1921
1468
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Activator
1447
Activator
1447
Hydrolytic Enzyme
38
ultraviolet B-induced damage
38
Target ID: ultraviolet B-induced damage
Interacts
323
Activator
1447
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1076
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8583
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8583
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
Approved
8583
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
Approved
8583
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8583
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
665
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
665
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
Intense 2.7μm emission in Er3+ doped zinc fluoride glass.
2017-05-15
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016-10-01
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.
2016-10
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016-09-21
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016-09
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.
2016-03-05
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
2015-09
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
2015-09
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.
2015-04-02
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design.
2015
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.
2014-11-04
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014-07-01
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014-05-16
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014-05-16
Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
2014-05-15
Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
2014-05
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014-04
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014-03-03
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014-01
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013-12
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013-11-25
Inorganic salts in atmospheric particulate matter: Raman spectroscopy as an analytical tool.
2013-11
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013-09
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013-07-31
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013-03
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013-01
Glucarpidase for the treatment of life-threatening methotrexate overdose.
2012-11
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012-06-25
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012-05-05
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012-04
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012-03
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide.
2012-03
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012-02
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.
2012-02
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011-12
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.
2011-11-30
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011-11
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011-09
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011-07
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
2011-06
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.
2011-03-21
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?
2011-03-01
Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.
2010-12
Glucarpidase following high-dose methotrexate: update on development.
2010-01
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
2007-11
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000-09
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994-12
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990-01
In vitro activity of zinc salts against human rhinoviruses.
1987-04
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
single intravenous injection of 50 Units per kg
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:36:35 GMT 2025
Edited
by admin
on Mon Mar 31 17:36:35 GMT 2025
Record UNII
K72I3DEX9B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC CITRATE
INCI   MART.   MI   WHO-DD  
INCI  
Official Name English
CITRATED ZINC
VANDF  
Preferred Name English
CITRATED ZINC [VANDF]
Common Name English
2-HYDROXY-1,2,3-PROPANETRICARBOXYLIC ACID ZINC SALT
Common Name English
ZINC CITRATE [MART.]
Common Name English
ZINC CITRATE [MI]
Common Name English
Zinc citrate [WHO-DD]
Common Name English
Classification Tree Code System Code
DSLD 137 (Number of products:9660)
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID90889427
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
PRIMARY
ECHA (EC/EINECS)
208-901-2
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
PRIMARY
DRUG BANK
DB11154
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
PRIMARY
EVMPD
SUB15754MIG
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
PRIMARY
NCI_THESAURUS
C84247
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
PRIMARY
DAILYMED
K72I3DEX9B
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
CONCEPT Dietary Supplement
RXCUI
236911
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
PRIMARY RxNorm
MERCK INDEX
m11603
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
PRIMARY Merck Index
SMS_ID
100000089512
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
PRIMARY
PUBCHEM
11023
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
PRIMARY
FDA UNII
K72I3DEX9B
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
PRIMARY
CAS
546-46-3
Created by admin on Mon Mar 31 17:36:35 GMT 2025 , Edited by admin on Mon Mar 31 17:36:35 GMT 2025
PRIMARY
Related Record Type Details
Structure of ZINC CITRATE DIHYDRATE
SOLVATE->ANHYDROUS
Structure of ZINC CATION
PARENT -> SALT/SOLVATE
Structure of ZINC CITRATE TRIHYDRATE
SOLVATE->ANHYDROUS
Structure of Anhydrous citric acid
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ZINC CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966